These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26835809)

  • 1. U-200 Humalog Insulin Now Available in United States.
    Chabanuk AJ
    Home Healthc Now; 2016 Feb; 34(2):102. PubMed ID: 26835809
    [No Abstract]   [Full Text] [Related]  

  • 2. [Humalog® 200 U/ml KwikPen™].
    Scheen AJ
    Rev Med Liege; 2015 Oct; 70(10):527-31. PubMed ID: 26727843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lyumjev - a new insulin lispro for diabetes.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):162-163. PubMed ID: 33429408
    [No Abstract]   [Full Text] [Related]  

  • 4. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
    Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
    Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin analogues: new agents for improving glycemic control.
    White JR; Campbell RK; Hirsch I
    Postgrad Med; 1997 Feb; 101(2):58-60, 63-5, 70. PubMed ID: 9046926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin lispro (Humalog), a novel fast-acting insulin analogue for the treatment of diabetes mellitus: overview of pharmacological and clinical data.
    Hermans MP; Nobels FR; De Leeuw I
    Acta Clin Belg; 1999 Oct; 54(5):233-40. PubMed ID: 10555380
    [No Abstract]   [Full Text] [Related]  

  • 7. In brief: Another insulin lispro (Admelog) for diabetes.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):e109. PubMed ID: 29913477
    [No Abstract]   [Full Text] [Related]  

  • 8. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
    Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
    Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin lispro (Humalog) in the treatment of diabetes mellitus: overview of belgian clinical data from global studies.
    Bex M; Buysschaert M; De Leeuw I; De Schepper J; Fery F; Hermans MP; Keymeulen B; Lauvaux JP; Letiexhe M; Mathieu C; Nobels FR; Rottiers R; Scheen A; Schmitt H; Van Crombrugge P; Van Gaal L
    Acta Clin Belg; 1999 Oct; 54(5):241-5. PubMed ID: 10555381
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulin confusion: an observation.
    Phillips W; Lando H
    Diabetes Care; 2002 Jun; 25(6):1103-4. PubMed ID: 12032129
    [No Abstract]   [Full Text] [Related]  

  • 11. Safe and appropriate use of insulin and other antihyperglycemic agents in hospital.
    Cornish W
    Can J Diabetes; 2014 Apr; 38(2):94-100. PubMed ID: 24690504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin lispro (HUMALOG KWIKPEN) double concentration (200 units/ml). Risk of confusion.
    Prescrire Int; 2016 Feb; 25(168):40. PubMed ID: 27042728
    [No Abstract]   [Full Text] [Related]  

  • 13. Benefits of lispro insulin: control of postprandial glucose levels is within reach.
    Bohannon NJ
    Postgrad Med; 1997 Feb; 101(2):73-6, 79-80. PubMed ID: 9046927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.
    Dungan KM; Buse JB; Herman WH; Arakaki RF; Jiang HH; Jacobson JG; Fahrbach JL
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e66-9. PubMed ID: 22421598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
    MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
    [No Abstract]   [Full Text] [Related]  

  • 16. Integrating advances in insulin into clinical practice: Advances In insulin formulations.
    King A
    J Fam Pract; 2013 Sep; 62(9 Suppl Insulin):S9-17. PubMed ID: 24080573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinopathy risk: what is responsible? Hormones, hyperglycemia, or humalog? Response to Kitzmiller et al.
    Jovanovic L
    Diabetes Care; 1999 May; 22(5):846-8. PubMed ID: 10332693
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypoglycemia in Diabetes Mellitus.
    Home Healthc Now; 2017 Sep; 35(8):E1-E2. PubMed ID: 28857877
    [No Abstract]   [Full Text] [Related]  

  • 19. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin lispro: its role in the treatment of diabetes mellitus.
    Campbell RK; Campbell LK; White JR
    Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.